Tamas Korcsmaros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tamas Korcsmaros has a total of 781 co-authors. Here are the top co-authors by number of shared publications:
- Marton Olbei
Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom
24 shared publications - Dezső Módos
Department of Metabolism, Digestion, and Reproduction, Imperial College London, London W12 0NN, UK
23 shared publications Matthew Madgwick
Gut Microbes and Health Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK
23 shared publicationsPadhmanand Sudhakar
Quadram Institute Bioscience, Norwich Research Park , Norwich, NR4 7UQ
21 shared publications- Padhmanand Sudhakar
Earlham Institute, Norwich Research Park, Norwich, UK
20 shared publications Axel Behrens
19 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in Nature Communications
Temporal strain-resolved metagenomics associates IBD dysbiosis with gastrointestinal inflammation
The gut microbiome in inflammatory bowel disease (IBD) is enriched in proinflammatory bacteria, yet defining a consistent dysbiotic signature is challenging, due to substantial variation between individuals and over time. We performed a high-resolution meta-analysis of 4,839 public metagenomes to disentangle the effects of IBD subtypes, inflammation, temporal, and individual variability. After accounting for temporal variation, we show that IBD-associated dysbiosis was characterized primarily by relative depletion of commensal bacteria rather than expansion of disease-associated taxa, together with increased microbiome variability both within and between individuals. Although 30% of species were IBD-associated, only 73% of these associations remained consistent across all timepoints. IBD-associated bacteria showed reduced persistence within hosts, increased strain loss and diminished strain engraftment. 8% of commensal species displayed strain-level associations with IBD that were independent of species-level changes, suggesting distinct ecological strategies for persistence. Finally, defining an inflammatory index, we demonstrated that inflammation explains much of the observed variation in microbial composition and abundance. Together, our findings indicate that inflammation associates and likely contributes to loss of commensals, thereby limiting microbiome recovery and resilience.
- 21 October 2026
- Published by Springer Nature in Nature Communications
Open AccessTemporal strain-resolved metagenomics associates IBD dysbiosis with gastrointestinal inflammation
The gut microbiome in inflammatory bowel disease (IBD) is enriched in proinflammatory bacteria, yet defining a consistent dysbiotic signature is challenging, due to substantial variation between individuals and over time. We performed a high-resolution meta-analysis of 4,839 public metagenomes to disentangle the effects of IBD subtypes, inflammation, temporal, and individual variability. After accounting for temporal variation, we show that IBD-associated dysbiosis was characterized primarily by relative depletion of commensal bacteria rather than expansion of disease-associated taxa, together with increased microbiome variability both within and between individuals. Although 30% of species were IBD-associated, only 73% of these associations remained consistent across all timepoints. IBD-associated bacteria showed reduced persistence within hosts, increased strain loss and diminished strain engraftment. 8% of commensal species displayed strain-level associations with IBD that were independent of species-level changes, suggesting distinct ecological strategies for persistence. Finally, defining an inflammatory index, we demonstrated that inflammation explains much of the observed variation in microbial composition and abundance. Together, our findings indicate that inflammation associates and likely contributes to loss of commensals, thereby limiting microbiome recovery and resilience.
- Open Access
The Human Gut Cell Atlas v1.0: A Unified, Community-Built Reference of Cellular Diversity Across the Gut
Single-cell RNA-sequencing (scRNA-seq) studies have transformed our understanding of cellular diversity in the human intestine, but differences in anatomical sampling, experimental processing and cell-type nomenclature limit comparison across datasets. Here, we present the Human Gut Cell Atlas (HGCA) V1, a community-curated reference of 944,390 healthy and disease-adjacent intestinal cells from 502 samples, 265 donors and 24 landmark studies, linked to detailed anatomical, clinical, and technical metadata. As this metadata is of critical importance to human biology, we developed MetaManager, an open source data management framework for standardized metadata collection and tracking. A five-level consensus taxonomy resolves 94 homeostatic cell identities and enables transferrable, high-resolution annotation of new gut datasets. By assembling cell identity, sampling metadata, and independent spatial validation, intestinal segment and radial tissue depth were revealed to systematically shape cellular composition and transcriptional state, enabling inference of the presence of sampling-dependent tissue niches, including lymphoid follicles. Reference mapping accurately and rapidly recovered cohort-level Crohn’s disease and treatment signatures without de novo annotation, while mapping human intestinal organoids quantified cell-type-specific identity, regional specification, maturation, and transcriptional fidelity to native tissue. The HGCA V1 provides a standardized cellular, anatomical coordinate, and metadata system for reproducible, high-quality analysis of intestinal biology across healthy tissue, disease-associated remodelling, and experimental models, providing a continuously evolving community reference for cumulative discovery in human intestinal biology.
Open AccessThe Human Gut Cell Atlas v1.0: A Unified, Community-Built Reference of Cellular Diversity Across the Gut
Single-cell RNA-sequencing (scRNA-seq) studies have transformed our understanding of cellular diversity in the human intestine, but differences in anatomical sampling, experimental processing and cell-type nomenclature limit comparison across datasets. Here, we present the Human Gut Cell Atlas (HGCA) V1, a community-curated reference of 944,390 healthy and disease-adjacent intestinal cells from 502 samples, 265 donors and 24 landmark studies, linked to detailed anatomical, clinical, and technical metadata. As this metadata is of critical importance to human biology, we developed MetaManager, an open source data management framework for standardized metadata collection and tracking. A five-level consensus taxonomy resolves 94 homeostatic cell identities and enables transferrable, high-resolution annotation of new gut datasets. By assembling cell identity, sampling metadata, and independent spatial validation, intestinal segment and radial tissue depth were revealed to systematically shape cellular composition and transcriptional state, enabling inference of the presence of sampling-dependent tissue niches, including lymphoid follicles. Reference mapping accurately and rapidly recovered cohort-level Crohn’s disease and treatment signatures without de novo annotation, while mapping human intestinal organoids quantified cell-type-specific identity, regional specification, maturation, and transcriptional fidelity to native tissue. The HGCA V1 provides a standardized cellular, anatomical coordinate, and metadata system for reproducible, high-quality analysis of intestinal biology across healthy tissue, disease-associated remodelling, and experimental models, providing a continuously evolving community reference for cumulative discovery in human intestinal biology.
- Open Access
Cytokine interaction networks, not individual cytokines, drive anti-TNF response in Crohn’s disease
Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract for which anti-tumour necrosis factor (anti-TNF) agents remain a first-line biologic therapy. However, remission rates are modest, and the mechanistic basis of non-response is poorly characterised. A common resistance mechanism is thought to emerge when alternative inflammatory cascades compensate for TNF inhibition, but the interactions underlying this rewiring have not been systematically characterised. We applied CytokineLink, our previously developed systems immunology framework, to single-cell RNA sequencing data from CD patients sampled before and after anti-TNF therapy. We reconstructed networks of interacting cytokines across samples stratified by treatment phase, response, and inflammation status, and identified condition-specific cytokine interactions and feedback loops, statistically validated against degree-matched random networks. We clustered the generated networks based on their inflammation, response, and treatment status. The pre-treatment inflamed non-responder network contained the largest set of unique interactions, organised around a connected module driven by IL17C targeting downstream TNF, IL6, IL1B, CXCL1/2/3/8, and CCL20. IL17C was produced by a population of non-ileal enteroendocrine cells, differentially abundant at baseline in non-responders. Gene set variation analysis in an independent cohort confirmed elevated non-responder module activity in colonic tissues of non-responders. Feedback loop analysis revealed that responder networks were characterised by persistent IL10 circuits sustained by macrophage populations and acquired tissue-remodelling interactions after therapy, whereas non-responders lost IL10 feedback loops post-treatment and gained TNF-containing motifs, including circuits signalling through the upstream activator TL1A. Our findings characterise the mechanism of anti-TNF non-response as a cytokine network, in which pre-existing epithelial-driven inflammatory modules and the failure to preserve regulatory feedback sustain TNF-independent inflammation in CD. By characterising cytokine interactions at the systems level, our approach moves beyond single-cytokine models of anti-TNF resistance to provide a mechanistic framework for understanding the biological basis of treatment failure in immune mediated diseases.
Open AccessCytokine interaction networks, not individual cytokines, drive anti-TNF response in Crohn’s disease
Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract for which anti-tumour necrosis factor (anti-TNF) agents remain a first-line biologic therapy. However, remission rates are modest, and the mechanistic basis of non-response is poorly characterised. A common resistance mechanism is thought to emerge when alternative inflammatory cascades compensate for TNF inhibition, but the interactions underlying this rewiring have not been systematically characterised. We applied CytokineLink, our previously developed systems immunology framework, to single-cell RNA sequencing data from CD patients sampled before and after anti-TNF therapy. We reconstructed networks of interacting cytokines across samples stratified by treatment phase, response, and inflammation status, and identified condition-specific cytokine interactions and feedback loops, statistically validated against degree-matched random networks. We clustered the generated networks based on their inflammation, response, and treatment status. The pre-treatment inflamed non-responder network contained the largest set of unique interactions, organised around a connected module driven by IL17C targeting downstream TNF, IL6, IL1B, CXCL1/2/3/8, and CCL20. IL17C was produced by a population of non-ileal enteroendocrine cells, differentially abundant at baseline in non-responders. Gene set variation analysis in an independent cohort confirmed elevated non-responder module activity in colonic tissues of non-responders. Feedback loop analysis revealed that responder networks were characterised by persistent IL10 circuits sustained by macrophage populations and acquired tissue-remodelling interactions after therapy, whereas non-responders lost IL10 feedback loops post-treatment and gained TNF-containing motifs, including circuits signalling through the upstream activator TL1A. Our findings characterise the mechanism of anti-TNF non-response as a cytokine network, in which pre-existing epithelial-driven inflammatory modules and the failure to preserve regulatory feedback sustain TNF-independent inflammation in CD. By characterising cytokine interactions at the systems level, our approach moves beyond single-cytokine models of anti-TNF resistance to provide a mechanistic framework for understanding the biological basis of treatment failure in immune mediated diseases.
- Open Access
Epithelial regulatory networks link non-coding genetic variation to clinical heterogeneity in ulcerative colitis
Ulcerative colitis (UC) is a genetically heterogeneous disease causing chronic intestinal inflammation. Genome-wide association studies have linked numerous non-coding single nucleotide polymorphisms (SNPs) to UC, yet how these variants relate to intestinal epithelial function and clinical outcomes remains largely unknown. To address this, we aimed to reconstruct patient-specific epithelial signalling and regulatory networks perturbed by non-coding SNPs and to dissect patient heterogeneity in a large UC phase 3 trial. We analysed genotype data from 452 participants in the etrolizumab phase 3 HICKORY cohort using the integrated SNP network platform (iSNP) to map the downstream effects of non-coding SNPs and identify transcription factors (TFs) they perturb in each patient. TFs were filtered to retain those with differential regulatory activity in UC epithelial cells, patients were stratified by these TF profiles, and clusters were correlated with etrolizumab outcomes. We identified 14 SNP-propagated TFs with differential epithelial regulatory activity. Unsupervised clustering stratified patients into subgroups differing in disease severity and treatment response: two clusters had the highest severity and lowest remission and response rates, whereas two others had the best outcomes. iSNP-based clustering improved endoscopic healing prediction (p = 0.03), with trends for clinical response and histological endoscopic mucosal improvement. This systems genomics framework links patient-specific non-coding SNPs to epithelial signalling and regulatory networks in UC and captures clinically meaningful heterogeneity associated with treatment outcomes. It supports genetics-informed precision medicine and improved clinical trial design in inflammatory bowel disease and beyond.
Open AccessEpithelial regulatory networks link non-coding genetic variation to clinical heterogeneity in ulcerative colitis
Ulcerative colitis (UC) is a genetically heterogeneous disease causing chronic intestinal inflammation. Genome-wide association studies have linked numerous non-coding single nucleotide polymorphisms (SNPs) to UC, yet how these variants relate to intestinal epithelial function and clinical outcomes remains largely unknown. To address this, we aimed to reconstruct patient-specific epithelial signalling and regulatory networks perturbed by non-coding SNPs and to dissect patient heterogeneity in a large UC phase 3 trial. We analysed genotype data from 452 participants in the etrolizumab phase 3 HICKORY cohort using the integrated SNP network platform (iSNP) to map the downstream effects of non-coding SNPs and identify transcription factors (TFs) they perturb in each patient. TFs were filtered to retain those with differential regulatory activity in UC epithelial cells, patients were stratified by these TF profiles, and clusters were correlated with etrolizumab outcomes. We identified 14 SNP-propagated TFs with differential epithelial regulatory activity. Unsupervised clustering stratified patients into subgroups differing in disease severity and treatment response: two clusters had the highest severity and lowest remission and response rates, whereas two others had the best outcomes. iSNP-based clustering improved endoscopic healing prediction (p = 0.03), with trends for clinical response and histological endoscopic mucosal improvement. This systems genomics framework links patient-specific non-coding SNPs to epithelial signalling and regulatory networks in UC and captures clinically meaningful heterogeneity associated with treatment outcomes. It supports genetics-informed precision medicine and improved clinical trial design in inflammatory bowel disease and beyond.
- 21 July 2026
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 45 (10) , 475-479
From Single Cytokines to Networks: A Systems Immunology View of Ulcerative Colitis
Ulcerative colitis (UC) is a chronic immune-mediated disorder of the gastrointestinal tract underpinned by dysregulated mucosal immune responses. Although biological therapies targeting individual cytokines have improved clinical outcomes, most patients fail to achieve durable remission, highlighting the limitations of single-target approaches. Emerging evidence suggests that cytokines function not in isolation but within highly interconnected signaling networks. Systems-level analyses using single-cell transcriptomics and network-based reconstruction reveal that UC phenotypes are characterized by specific rewiring of cytokine communication. Longitudinal multi-omics data, ex vivo perturbation models, and spatial transcriptomics offer opportunities to extend this framework by resolving the spatiotemporal dynamics of cytokine communication across disease states. Integration with systems genomics and microbial–metabolic networks could further refine patient-specific cytokine models. Together, this multi-layered framework supports a paradigm shift away from reductionist, single-cytokine approaches toward a dynamic, spatially organized, and genetically constrained systems immunology perspective of mucosal inflammation, informing novel precision medicine strategies.
- 21 July 2026
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 45 (10) , 475-479
From Single Cytokines to Networks: A Systems Immunology View of Ulcerative Colitis
Ulcerative colitis (UC) is a chronic immune-mediated disorder of the gastrointestinal tract underpinned by dysregulated mucosal immune responses. Although biological therapies targeting individual cytokines have improved clinical outcomes, most patients fail to achieve durable remission, highlighting the limitations of single-target approaches. Emerging evidence suggests that cytokines function not in isolation but within highly interconnected signaling networks. Systems-level analyses using single-cell transcriptomics and network-based reconstruction reveal that UC phenotypes are characterized by specific rewiring of cytokine communication. Longitudinal multi-omics data, ex vivo perturbation models, and spatial transcriptomics offer opportunities to extend this framework by resolving the spatiotemporal dynamics of cytokine communication across disease states. Integration with systems genomics and microbial–metabolic networks could further refine patient-specific cytokine models. Together, this multi-layered framework supports a paradigm shift away from reductionist, single-cytokine approaches toward a dynamic, spatially organized, and genetically constrained systems immunology perspective of mucosal inflammation, informing novel precision medicine strategies.
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (4)
A historical journey of metabolite–protein interaction discovery: from data harmonization to AI-driven prediction
Metabolites are life-sustaining small molecules produced by living organisms. They interact with proteins involved in metabolism, signalling, and gene regulation, called metabolite–protein interactions (MPIs). This review traces the history of MPI research, from curated resources and early cheminformatics to harmonized identifiers, proteome-scale structural models, and artificial intelligence–driven prediction, while highlighting persistent challenges that continue to limit mechanistic interpretation of metabolomics. Early small-molecule-protein interaction prediction tools (e.g. Molpat and Catalyst) and resources (e.g. ChEMBL and BindingDB) were typically biased towards drug-like molecules. As drug-centred research continued, a revolution in large-scale metabolomics enabled high-throughput profiling of metabolite levels across physiological and disease states. However, these advances also introduced major data integration challenges such as data fragmentation, unresolved metabolite identities, and limited physiological context. Subsequent metabolite-centric resources (e.g. HMDB) and high-throughput screens applied to MPI detection (e.g. thermal proteome profiling) have partially addressed this bias. Proteome-scale structure prediction (e.g. AlphaFold) has further incentivized research into the effects of metabolites on protein structure and function. Nevertheless, the complexity of the biological response also depends on, e.g. exposure, access, and target expression. Looking ahead, MPI research is likely to be shaped by structure-aware deep learning and the integration of MPIs with comprehensive single-cell multi-omics data and host–microbe modelling. These advances may turn metabolomic signals into causal, testable hypotheses, enabling robust systems-level MPI maps for identifying intervention points and designing new treatments. We propose a historically structured roadmap centred on standards-driven data integration and calibrated, structure-aware modelling to support mechanistic, systems-level MPI maps.
- 3 July 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (4)
Open AccessA historical journey of metabolite–protein interaction discovery: from data harmonization to AI-driven prediction
Metabolites are life-sustaining small molecules produced by living organisms. They interact with proteins involved in metabolism, signalling, and gene regulation, called metabolite–protein interactions (MPIs). This review traces the history of MPI research, from curated resources and early cheminformatics to harmonized identifiers, proteome-scale structural models, and artificial intelligence–driven prediction, while highlighting persistent challenges that continue to limit mechanistic interpretation of metabolomics. Early small-molecule-protein interaction prediction tools (e.g. Molpat and Catalyst) and resources (e.g. ChEMBL and BindingDB) were typically biased towards drug-like molecules. As drug-centred research continued, a revolution in large-scale metabolomics enabled high-throughput profiling of metabolite levels across physiological and disease states. However, these advances also introduced major data integration challenges such as data fragmentation, unresolved metabolite identities, and limited physiological context. Subsequent metabolite-centric resources (e.g. HMDB) and high-throughput screens applied to MPI detection (e.g. thermal proteome profiling) have partially addressed this bias. Proteome-scale structure prediction (e.g. AlphaFold) has further incentivized research into the effects of metabolites on protein structure and function. Nevertheless, the complexity of the biological response also depends on, e.g. exposure, access, and target expression. Looking ahead, MPI research is likely to be shaped by structure-aware deep learning and the integration of MPIs with comprehensive single-cell multi-omics data and host–microbe modelling. These advances may turn metabolomic signals into causal, testable hypotheses, enabling robust systems-level MPI maps for identifying intervention points and designing new treatments. We propose a historically structured roadmap centred on standards-driven data integration and calibrated, structure-aware modelling to support mechanistic, systems-level MPI maps.
- Open Access
OmniPath Metabo: chemical structures, interactions and mechanisms to study the metabolome
Mechanistic and functional analysis of omics data largely relies on the incorporation of prior knowledge; however, connecting metabolomics data and knowledge is a major methodological challenge. This is largely driven by the diverse prior knowledge being fragmented across many databases requiring the merging of different database records across chemical structures, identifiers, and varying levels of structural specificity. Hence, this limits mechanistic interpretation and functional characterisation of the metabolome. Here, we present OmniPath Metabo, a comprehensive, harmonized, metabolome-centric database covering metabolites, lipids, food-derived compounds, and small molecule drugs, along with their associated receptors, transporters, enzymes, reactions, allosteric regulators, and disease associations. OmniPath Metabo harmonizes attributes using controlled vocabularies and ontologies, structures and built-in cheminformatics to map identifiers and track ambiguity. OmniPath Metabo is built directly from 40+ original resources and is freely accessible via an interactive web app and API at metabo.omnipathdb.org . OmniPath Metabo enables dynamic, context-specific construction of subnetworks to serve dedicated purposes, such as cell-cell communication or integrated multi-omics metabolite-driven regulation, connecting reactions, allosteric regulation, metabolite-receptor and metabolite-transporter interactions. Combining it with the over 170 other resources in OmniPath, it can be used for integrated networks of signaling, gene regulation, and metabolism. We showcase the application of OmniPath Metabo by analysing publicly available metabolomics data of lung cancer cell lines and metabolic footprints to mutational patterns. In summary, OmniPath Metabo transforms fragmented resources into a harmonised prior knowledge framework for a mechanistic and functional analysis of the metabolome.
Open AccessOmniPath Metabo: chemical structures, interactions and mechanisms to study the metabolome
Mechanistic and functional analysis of omics data largely relies on the incorporation of prior knowledge; however, connecting metabolomics data and knowledge is a major methodological challenge. This is largely driven by the diverse prior knowledge being fragmented across many databases requiring the merging of different database records across chemical structures, identifiers, and varying levels of structural specificity. Hence, this limits mechanistic interpretation and functional characterisation of the metabolome. Here, we present OmniPath Metabo, a comprehensive, harmonized, metabolome-centric database covering metabolites, lipids, food-derived compounds, and small molecule drugs, along with their associated receptors, transporters, enzymes, reactions, allosteric regulators, and disease associations. OmniPath Metabo harmonizes attributes using controlled vocabularies and ontologies, structures and built-in cheminformatics to map identifiers and track ambiguity. OmniPath Metabo is built directly from 40+ original resources and is freely accessible via an interactive web app and API at metabo.omnipathdb.org . OmniPath Metabo enables dynamic, context-specific construction of subnetworks to serve dedicated purposes, such as cell-cell communication or integrated multi-omics metabolite-driven regulation, connecting reactions, allosteric regulation, metabolite-receptor and metabolite-transporter interactions. Combining it with the over 170 other resources in OmniPath, it can be used for integrated networks of signaling, gene regulation, and metabolism. We showcase the application of OmniPath Metabo by analysing publicly available metabolomics data of lung cancer cell lines and metabolic footprints to mutational patterns. In summary, OmniPath Metabo transforms fragmented resources into a harmonised prior knowledge framework for a mechanistic and functional analysis of the metabolome.
- Open Access
- 9 June 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (14) , 1-33
GBP1 recruitment to actin-rich pedestals of extracellular Gram-negative bacteria promotes pyroptosis
The IFNγ-induced GTPase guanylate-binding protein 1 (GBP1) binds to lipopolysaccharide (LPS) on cytosolic gram-negative bacteria and promotes pyroptosis via the recruitment and activation of caspase-4 on the bacterial outer membrane. Enteropathogenic and enterohaemorrhagic Escherichia coli (EPEC and EHEC, respectively) are extracellular pathogens that adhere to host cells and stimulate dense actin polymerisation underneath their attachment sites, generating structures described as actin-rich pedestals. Here, we show that GBP1 traffics to actin-rich pedestals in human cells infected with EPEC or EHEC in vitro and mouse colonocytes infected with the EPEC-like murine pathogen Citrobacter rodentium in vivo. GBP1 promotes caspase-4 recruitment to actin-rich pedestals, leading to pyroptosis and IL-18 release. GBP1 mutants defective in LPS coatomer formation also localise to EPEC pedestals. A novel assay that mimics pathogenic effector activity reveals GBP1 recruitment to sterile actin polymerisation sites. We conclude that cytosolic GBP1 is mobilised to sites of pathogen-induced actin remodelling independently of LPS. Our study establishes that GBP1 not only operates as a pattern-recognition receptor but also orchestrates effector-triggered immunity against pathogens that hijack the actin cytoskeleton.
- 9 June 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (14) , 1-33
Open AccessGBP1 recruitment to actin-rich pedestals of extracellular Gram-negative bacteria promotes pyroptosis
The IFNγ-induced GTPase guanylate-binding protein 1 (GBP1) binds to lipopolysaccharide (LPS) on cytosolic gram-negative bacteria and promotes pyroptosis via the recruitment and activation of caspase-4 on the bacterial outer membrane. Enteropathogenic and enterohaemorrhagic Escherichia coli (EPEC and EHEC, respectively) are extracellular pathogens that adhere to host cells and stimulate dense actin polymerisation underneath their attachment sites, generating structures described as actin-rich pedestals. Here, we show that GBP1 traffics to actin-rich pedestals in human cells infected with EPEC or EHEC in vitro and mouse colonocytes infected with the EPEC-like murine pathogen Citrobacter rodentium in vivo. GBP1 promotes caspase-4 recruitment to actin-rich pedestals, leading to pyroptosis and IL-18 release. GBP1 mutants defective in LPS coatomer formation also localise to EPEC pedestals. A novel assay that mimics pathogenic effector activity reveals GBP1 recruitment to sterile actin polymerisation sites. We conclude that cytosolic GBP1 is mobilised to sites of pathogen-induced actin remodelling independently of LPS. Our study establishes that GBP1 not only operates as a pattern-recognition receptor but also orchestrates effector-triggered immunity against pathogens that hijack the actin cytoskeleton.
- Open Access
- 21 April 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (4) , e0123925
SalmonAct deciphers transcription factor regulatory activity in Salmonella transcriptomics
Foodborne Salmonella enterica infection remains a major public health threat due to its prevalence in food, ease of transmission, and increasing antibiotic resistance. Consequently, understanding the molecular mechanisms underlying Salmonella pathogenesis is crucial for guiding novel diagnostic, preventative, and therapeutic approaches. High-throughput transcriptomic technologies are now often employed in Salmonella research to quantify how gene expression changes in response to various conditions or mutations. But due to the high dimensionality of this data, resulting from the comparison of the expression of thousands of genes from multiple strains or culture conditions with complex interactions, interpretation remains a demanding task. To address this issue, we present SalmonAct, a comprehensive signed and directed prior knowledge resource for inferring transcription factor activities in Salmonella . This new resource expands the toolkit available for Salmonella functional analysis. Built as an extension of the SalmoNet2 database, SalmonAct can be used to infer the activity of 191 transcription factors in 5,991 regulatory interactions based on publicly available interaction and regulatory knockout data. SalmonAct enhances the interpretation of highly dimensional transcriptomic data by identifying both highly influential and minimally active transcription factors that drive the observed expression state. SalmonAct aids in bridging the gap between model and non-model organisms' functional analysis, and together with the SalmoNet2 resource, can be used for further downstream data analyses. IMPORTANCE: While modern high-throughput transcriptomics technologies provide effective ways of studying Salmonella enterica , the complexity of these datasets makes interpretation challenging. SalmonAct provides a new computational resource to connect gene expression changes with the activity of transcription factors, key regulators of bacterial adaptation and virulence. SalmonAct can help researchers progress from the analysis of gene expression profiles towards a clearer understanding of the regulatory programs driving the behavior of the pathogen. By integrating prior knowledge of transcription factor-target gene relationships, SalmonAct contributes to uncovering novel mechanisms of bacterial pathogenesis and supports the development of new approaches to combat Salmonella infections.
- 21 April 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (4) , e0123925
Open AccessSalmonAct deciphers transcription factor regulatory activity in Salmonella transcriptomics
Foodborne Salmonella enterica infection remains a major public health threat due to its prevalence in food, ease of transmission, and increasing antibiotic resistance. Consequently, understanding the molecular mechanisms underlying Salmonella pathogenesis is crucial for guiding novel diagnostic, preventative, and therapeutic approaches. High-throughput transcriptomic technologies are now often employed in Salmonella research to quantify how gene expression changes in response to various conditions or mutations. But due to the high dimensionality of this data, resulting from the comparison of the expression of thousands of genes from multiple strains or culture conditions with complex interactions, interpretation remains a demanding task. To address this issue, we present SalmonAct, a comprehensive signed and directed prior knowledge resource for inferring transcription factor activities in Salmonella . This new resource expands the toolkit available for Salmonella functional analysis. Built as an extension of the SalmoNet2 database, SalmonAct can be used to infer the activity of 191 transcription factors in 5,991 regulatory interactions based on publicly available interaction and regulatory knockout data. SalmonAct enhances the interpretation of highly dimensional transcriptomic data by identifying both highly influential and minimally active transcription factors that drive the observed expression state. SalmonAct aids in bridging the gap between model and non-model organisms' functional analysis, and together with the SalmoNet2 resource, can be used for further downstream data analyses. IMPORTANCE: While modern high-throughput transcriptomics technologies provide effective ways of studying Salmonella enterica , the complexity of these datasets makes interpretation challenging. SalmonAct provides a new computational resource to connect gene expression changes with the activity of transcription factors, key regulators of bacterial adaptation and virulence. SalmonAct can help researchers progress from the analysis of gene expression profiles towards a clearer understanding of the regulatory programs driving the behavior of the pathogen. By integrating prior knowledge of transcription factor-target gene relationships, SalmonAct contributes to uncovering novel mechanisms of bacterial pathogenesis and supports the development of new approaches to combat Salmonella infections.
- 3 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (923) , eadt0986
Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targets
Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract that is characterized by dysregulated cytokine signaling. Treatment outcomes for patients with UC remain suboptimal despite the advent of cytokine-targeting therapies, necessitating a better understanding of the interconnected cytokine signaling networks that are perturbed in patients with UC. To address this, we undertook systems immunology modeling of single-cell transcriptomics data from colonic biopsies of treatment-naive and treatment-exposed patients with UC to build complex cytokine signaling networks underpinned by putative cytokine-cytokine interactions. The generated cytokine networks effectively captured known, physiologically relevant cytokine-cytokine interactions, which we validated in vitro in colonic epithelial organoids derived from patients with UC and with organoids cocultured with innate lymphoid cells. These networks revealed several previously unrecognized aspects of UC pathogenesis. These included the identification of a cytokine subnetwork that is unique to treatment-naive patients with UC, of cytokines with altered interaction patterns across UC disease states (including IL-22, TL1A, IL-23A, and OSM), and of cytokine-cytokine interactions that were mediated by specific members of the Janus-associated kinase (JAK) family. In particular, our network analysis positioned TL1A as an important upstream regulator of TNF and IL-23A (both of which are targeted by approved UC drugs) and suggested it as a potential therapeutic target. Together, these findings open several avenues for guiding future cytokine-targeting therapeutic approaches in UC, and the presented methodology can be readily applied to gain similar insights into other immune-mediated inflammatory diseases.
- 3 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (923) , eadt0986
Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targets
Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract that is characterized by dysregulated cytokine signaling. Treatment outcomes for patients with UC remain suboptimal despite the advent of cytokine-targeting therapies, necessitating a better understanding of the interconnected cytokine signaling networks that are perturbed in patients with UC. To address this, we undertook systems immunology modeling of single-cell transcriptomics data from colonic biopsies of treatment-naive and treatment-exposed patients with UC to build complex cytokine signaling networks underpinned by putative cytokine-cytokine interactions. The generated cytokine networks effectively captured known, physiologically relevant cytokine-cytokine interactions, which we validated in vitro in colonic epithelial organoids derived from patients with UC and with organoids cocultured with innate lymphoid cells. These networks revealed several previously unrecognized aspects of UC pathogenesis. These included the identification of a cytokine subnetwork that is unique to treatment-naive patients with UC, of cytokines with altered interaction patterns across UC disease states (including IL-22, TL1A, IL-23A, and OSM), and of cytokine-cytokine interactions that were mediated by specific members of the Janus-associated kinase (JAK) family. In particular, our network analysis positioned TL1A as an important upstream regulator of TNF and IL-23A (both of which are targeted by approved UC drugs) and suggested it as a potential therapeutic target. Together, these findings open several avenues for guiding future cytokine-targeting therapeutic approaches in UC, and the presented methodology can be readily applied to gain similar insights into other immune-mediated inflammatory diseases.